ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiovascular Research

Executive Summary: ML-7 hydrochloride (SKU: A3626) is a highly selective inhibitor of myosin light chain kinase (MLCK) with a Ki of 300 nM, enabling targeted modulation of myosin light chain (MLC) phosphorylation in muscle contraction and cell motility (APExBIO). The compound is extensively validated in ischemia/reperfusion injury and vascular endothelial dysfunction models, demonstrating significant improvements in heart contractility and tight junction protein regulation (DOI:10.1128/IAI.00233-19). ML-7 is soluble in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL, with warming), but insoluble in ethanol. It is intended exclusively for scientific research and should not be used in diagnostics or therapeutics. Product is supplied at approximately 98% purity by APExBIO for consistent experimental outcomes.

Biological Rationale

Myosin light chain kinase (MLCK) is a calcium/calmodulin-dependent serine/threonine kinase central to muscle contraction and cell motility. It phosphorylates myosin regulatory light chains, activating actomyosin ATPase and enabling force generation in smooth, cardiac, and non-muscle cells (APExBIO). Abnormal MLCK activity is implicated in cardiovascular diseases, atherosclerosis, and endothelial barrier dysfunction. ML-7 hydrochloride allows scientists to dissect these signaling events by selectively inhibiting MLCK, thus providing mechanistic insight into disease pathology and potential intervention points. Tight junction proteins (e.g., ZO1, occludin) and the cytoskeleton are regulated downstream of MLCK, linking its inhibition to vascular permeability and inflammation models (Wei et al., 2019).

Mechanism of Action of ML-7 hydrochloride

ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride) is a competitive inhibitor of the ATP-binding site of MLCK. By binding the kinase domain, it prevents phosphorylation of the myosin regulatory light chain. This inhibition disrupts actomyosin filament assembly, leading to reduced contractility in cardiac and smooth muscle, and altered cell motility in non-muscle cells. ML-7 is approximately 10-fold more selective for MLCK than for protein kinase C or cyclic nucleotide-dependent kinases. In vitro, ML-7 blocks neuregulin-1-induced sarcomeric organization in neonatal rat cardiomyocytes, confirming its specificity for the MLCK pathway. In vivo, it modulates proteins involved in energy metabolism and oxidative stress when administered before ischemia and during reperfusion in animal models.

Evidence & Benchmarks

• ML-7 hydrochloride inhibits MLCK with a Ki of 300 nM in biochemical assays, demonstrating high potency and selectivity (APExBIO).
• In neonatal rat cardiomyocytes, ML-7 blocks recombinant human neuregulin-1 (rhNRG-1)-stimulated restoration of sarcomeric organization, highlighting its functional impact on cardiac MLCK signaling (DOI:10.1128/IAI.00233-19).
• In rabbit models, ML-7 ameliorates vascular endothelial dysfunction and atherosclerosis by regulating tight junction proteins ZO1 and occludin through the MLCK/MLC pathway (DOI:10.1128/IAI.00233-19).
• ML-7 significantly improves heart contractility and regulates proteins linked to energy metabolism and oxidative stress in ischemia/reperfusion (I/R) injured hearts (DOI:10.1128/IAI.00233-19).
• ML-7's utility in dissecting MLCK-dependent endocytosis and cytoskeletal remodeling has been confirmed in Drosophila S2 cell models infected with Spiroplasma eriocheiris (DOI:10.1128/IAI.00233-19).

For advanced protocols and troubleshooting in cardiovascular models, see ML-7 Hydrochloride: A Selective MLCK Inhibitor for Next-G...—this article extends those methods by detailing in vivo endpoints and tight junction regulation.

For mechanistic insights into MLCK/MLC phosphorylation and tight junction protein regulation, consult ML-7 Hydrochloride: Unraveling MLCK Pathways in Cardiovas...; our article updates with latest data on energy metabolism modulation.

Applications, Limits & Misconceptions

ML-7 hydrochloride is validated in:

• Cardiovascular disease models (ischemia/reperfusion injury, atherosclerosis).
• Endothelial barrier function and vascular permeability studies.
• Cytoskeletal and tight junction protein regulation.
• Cellular motility, invasion, and wound healing assays.
• Dissection of MLCK-dependent signaling in non-muscle cells.

Its selectivity, solubility, and purity (∼98%) make it suitable for in vitro and in vivo research, but not for clinical use. For workflow optimization in cell viability and disease models, see ML-7 hydrochloride (SKU A3626): Optimizing MLCK Inhibitio...; this article clarifies long-term storage and short-term solution stability parameters.

Common Pitfalls or Misconceptions

• Not a broad-spectrum kinase inhibitor: ML-7 is selective for MLCK and does not broadly inhibit kinases like PKC or PKA at standard concentrations.
• Not intended for diagnostic or therapeutic use: APExBIO supplies ML-7 hydrochloride strictly for research applications; clinical use is not supported.
• Solubility limitations: ML-7 is insoluble in ethanol and requires DMSO or gentle warming in water for dissolution.
• Short-term solution stability: Solutions should be prepared fresh or stored at -20°C for limited periods to maintain activity.
• Species/model specificity: Functional outcomes may vary between mammalian and invertebrate systems due to differences in MLCK isoforms and signaling context.

Workflow Integration & Parameters

ML-7 hydrochloride is supplied as a powder with ≥98% purity. For most cell-based assays, dissolve in DMSO to a stock concentration of 10–20 mM; dilute in aqueous buffers for working concentrations typically between 1–10 μM. For in vivo protocols, refer to published dose-response studies, adjusting for animal weight and administration route. Store powder at -20°C in a desiccated environment; reconstituted solutions are stable for up to several days at -20°C, but repeated freeze-thaw cycles should be avoided. Always include appropriate controls (vehicle, non-inhibitory analogs) to ensure specificity. Refer to the ML-7 hydrochloride product page for detailed handling guidance.

Conclusion & Outlook

ML-7 hydrochloride remains a foundational tool in cardiovascular and cell motility research due to its high selectivity and well-characterized effects on MLCK-mediated phosphorylation. Its role in regulating cytoskeletal dynamics and barrier function continues to inform basic science and translational models of disease. As new MLCK isoform-specific inhibitors emerge, ML-7 provides a benchmark for efficacy and selectivity. APExBIO's A3626 formulation supports reproducible, data-driven research applications. For comprehensive mechanistic or translational perspectives, see ML-7 Hydrochloride: Advanced Insights into MLCK Inhibition…, which this article augments by detailing quantitative performance benchmarks and workflow integration.